Sanofi Invests €170M in French Facilities to Expand Flu Vaccine Supply
Sanofi Pasteur will expand its main vaccine manufacturing site to increase distribution of its quadrivalent flu vaccine VaxigripTetra around the world.
Sanofi will invest €170M in expanding its vaccine production facilities in Val de Reuil, France, which also hosts its global vaccine distribution center, from which it currently ships 900 million vaccine doses a year. The company plans to complete the expansion by 2021 and start producing vaccines in the new facility in 2022.
The goal is to increase the supply of VaxigripTetra, a quadrivalent flu vaccine that provides protection against two influenza A strains (H1N1 and H3N2) and two B strains (Victoria and Yamagata), complying with WHO recommendations. Approved last year, the vaccine is already available in 20 European countries. With the construction of the new facilities, Sanofi wants to expand the distribution of VaxigripTetra to up to 70 countries around the world.
With the global influenza vaccine market expected to reach €4.85Bn by 2022, Sanofi’s huge investment in scaling up its vaccine production capacity is clearly aimed at maintaining a strong position against the competition, which includes quadrivalent flu vaccines marketed by GlaxoSmithKline and Astrazeneca’s Medimmune.
Image via ricochet64 /Shutterstock